TABLE 3.
Multivariate linear regression analysis for AUC0–24 h prediction based on the genetic variants affecting the pharmacokinetics of atorvastatin.
| Associated gene | Variables | Code of genotypes | Estimate (B) | Standard Error of estimate | t-value | p-value | ||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | ||||||
| ABCB1 | rs2235029_C | A/A | A/C | C/C | −126.0 | 46.76 | −2.70 | 0.012 |
| ABCB1 | rs3214119_T | TC/TC | TC/T | T/T | 118.9 | 22.04 | 5.40 | <0.001 |
| ABCB1 | rs1922242_T | A/A | A/T | T/T | 60.0 | 14.65 | 4.09 | <0.001 |
| ABCG2 | rs759701118_A | G/G | G/A | A/A | 358.6 | 46.73 | 7.68 | <0.001 |
| APOA5 | rs33984246_G | A/A | A/G | G/G | 118.4 | 45.13 | 2.62 | 0.015 |
| APOA5 | rs3135507_T | C/C | C/T | T/T | −94.2 | 48.30 | −1.95 | 0.062 |
| CETP | rs12708974_T | C/C | C/T | T/T | −49.4 | 18.62 | −2.65 | 0.014 |
| CYP7A1 | rs3808607_T | G/G | G/T | T/T | 46.4 | 12.96 | 3.59 | 0.001 |
| — | Age | — | — | — | 2.7 | 0.83 | 3.31 | 0.003 |
| — | (Intercept) | — | — | — | 65.558 | 32.56 | 2.014 | 0.055 |
| Multivariate linear regression analysis for ATV AUC0-24 h prediction | ||||||||
| R2 | 0.911 | |||||||
| Adjusted R2 | 0.878 | |||||||
| F-statistic | 28.3 | |||||||
| p value | <0.001 | |||||||
| Equation for atorvastatin AUC0-24 h | ||||||||
| Atorvastatin AUC0–24 h = [65.558 + 2.737 × Age-49.444×rs12708974 (CETP) + 118.397 × rs33984246 (APOA5) + 46.449×rs3808607 (CYP7A1)−94.225 × rs3135507 (APOA5)−126.04 × rs2235029 (ABCB1) + 118.925 × rs3214119 (ABCB1) + 59.991 × rs1922242 (ABCB1) + 358.648 × r s759701118 (ABCG2)] × 80/dosage | ||||||||
Eight genetic variants (ABCB1 rs2235029_C, rs3214119_T, rs1922242_T; ABCG2 rs759701118_A; APOA5 rs33984246_G, rs3135507_T; CETP, rs12708974_T; CYP7A1 rs3808607_T) and age showed significant association with the ATV AUC, in the multivariate linear regression analysis.